vs
Side-by-side financial comparison of ROBO.AI INC. (AIIO) and Applied Therapeutics, Inc. (APLT). Click either name above to swap in a different company.
Applied Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $864.0K, roughly 1.2× ROBO.AI INC.). ROBO.AI INC. runs the higher net margin — -258.8% vs -1899.0%, a 1640.2% gap on every dollar of revenue.
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
AIIO vs APLT — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $864.0K | $1.0M |
| Net Profit | $-2.2M | $-19.0M |
| Gross Margin | — | — |
| Operating Margin | -735.9% | -1675.8% |
| Net Margin | -258.8% | -1899.0% |
| Revenue YoY | — | 719.7% |
| Net Profit YoY | — | 72.3% |
| EPS (diluted) | $-0.01 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $1.0M | ||
| Q2 25 | $864.0K | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $-1.0K | ||
| Q2 24 | — | $144.0K | ||
| Q1 24 | — | $190.0K | ||
| Q4 23 | — | $-667.0K | ||
| Q3 23 | — | $0 |
| Q3 25 | — | $-19.0M | ||
| Q2 25 | $-2.2M | $-21.3M | ||
| Q1 25 | — | $-21.8M | ||
| Q4 24 | — | $44.0M | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | — | $-83.9M | ||
| Q4 23 | — | $-37.7M | ||
| Q3 23 | — | $-42.4M |
| Q3 25 | — | -1675.8% | ||
| Q2 25 | -735.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3302300.0% | ||
| Q2 24 | — | -14194.4% | ||
| Q1 24 | — | -11101.6% | ||
| Q4 23 | — | 3149.3% | ||
| Q3 23 | — | — |
| Q3 25 | — | -1899.0% | ||
| Q2 25 | -258.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4400700.0% | ||
| Q2 24 | — | 2012.5% | ||
| Q1 24 | — | -44177.9% | ||
| Q4 23 | — | 5649.0% | ||
| Q3 23 | — | — |
| Q3 25 | — | $-0.13 | ||
| Q2 25 | $-0.01 | $-0.15 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.52 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.67 | ||
| Q4 23 | — | $-0.40 | ||
| Q3 23 | — | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.0K | $11.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-65.1M | $-561.0K |
| Total Assets | $34.9M | $34.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $11.9M | ||
| Q2 25 | $147.0K | $30.4M | ||
| Q1 25 | — | $50.8M | ||
| Q4 24 | — | $79.4M | ||
| Q2 24 | — | $122.2M | ||
| Q1 24 | — | $146.5M | ||
| Q4 23 | — | $49.9M | ||
| Q3 23 | — | $37.5M |
| Q3 25 | — | $-561.0K | ||
| Q2 25 | $-65.1M | $17.4M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $57.0M | ||
| Q2 24 | — | $72.4M | ||
| Q1 24 | — | $67.3M | ||
| Q4 23 | — | $-17.1M | ||
| Q3 23 | — | $-11.0M |
| Q3 25 | — | $34.4M | ||
| Q2 25 | $34.9M | $37.3M | ||
| Q1 25 | — | $56.9M | ||
| Q4 24 | — | $86.7M | ||
| Q2 24 | — | $127.8M | ||
| Q1 24 | — | $151.2M | ||
| Q4 23 | — | $54.8M | ||
| Q3 23 | — | $45.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-18.4M | ||
| Q2 25 | $-1.0M | $-20.3M | ||
| Q1 25 | — | $-28.6M | ||
| Q4 24 | — | $-19.5M | ||
| Q2 24 | — | $-22.6M | ||
| Q1 24 | — | $-18.9M | ||
| Q4 23 | — | $-17.0M | ||
| Q3 23 | — | $-14.7M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.44× | ||
| Q2 24 | — | -7.80× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
